![]() ![]() Gallagher’s career really took off when she became CEO of Calistoga Pharmaceuticals in 2008. One early career highlight: She was there at the beginning of marketing for rituximab (Rituxan), the monoclonal antibody. Gallagher has had ups and downs in a career that includes stops at Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen, CancerVax and Anadys Pharmaceuticals. Mehra serves on the board of gene therapy pioneer Spark Therapeutics (being acquired by Roche for $4.8 billion), participated in the investment in Merus (market value: $385 million) and invested in Parkinson’s drug developer Civitas Therapeutics (acquired by Acorda Therapeutics for $525 million). Jim Healy and Mike Powell are the long-tenured, better-known partners at Sofinnova, but Mehra has quietly built a solid track record. I’m not sure exactly what the last couple remarks mean, other than the guy doesn’t mind being a non-conformist, which counts for something in a business known for its herd mentality. Rolls up his sleeves and helps build some companies while also being a whip-smart traditional investor in others. ![]() One VC wrote: “Ben deserves to be on the list. ![]() Auspitz is also co-founder of gene therapy company Orchard Therapeutics (market value: $1.1 billion).īeyond those deals, Auspitz has invested in Ultragenyx Pharmaceutical (market cap: $2.5 billion), gene therapy company REGENX Bio (market cap: $1.2 billion), and gene editor Precision Biosciences (market cap: $383 million). Auspitz is a co-founder of gene therapy company Dimension Therapeutics (acquired by Ultragenyx for $151 million in Oct. “Best gene/cell therapy VC I can think of,” wrote one VC. “Key player in the growth of Vivo over the past decade as they have built a US/Asia model,” one Timmerman Report subscriber said of Cha. The firm, with offices in the San Francisco Bay Area, China, and Taiwan, has $2.2 billion under management. It often syndicates with OrbiMed Advisors. They include: Aspreva (acquired for $915 million in 2009), NextWave Pharmaceuticals (acquired for as much as $700 million in 2012), and Ceptaris (acquired for $250 million in 2013). He was an investor in Biohaven Pharmaceuticals (market value: $2.3 billion) and a few that went public and later fell on hard times, including Sierra Oncology, Menlo Therapeutics and Aclaris Therapeutics.Ĭha’s fingerprints are on a steady number of exits. He’s currently on the boards of Denmark-based Ascendis Pharma (market value: $4.6 billion) and Cambridge, Mass.-based KalVista Pharmaceuticals (market value: $196 million). That’s long enough to put together a track record. Albert Cha, Vivo CapitalĬha joined Vivo Capital in 2000. Quiet, really hard working…Not prone to self-promotion, just gets shit done.”įor more on Burow’s personal story, see a 2010 profile I wrote for Xconomy. Chemist by training, so ‘gets the science’ as well as anybody I’ve met. One entrepreneur said of Burow: “Total rock star. Receptos was acquired by Celgene for $7.2 billion in 2015. She helped reboot the company in 2008 with Ray Stevens and Bill Rastetter. Vir Biotechnology (infectious disease, S-1 IPO prospectus on file).īurow’s biggest home run was San Diego-based Receptos. ![]() Unity Biotechnology (anti-aging, publicly traded).Beam Therapeutics (DNA base editing, S-1 IPO prospectus on file).Gossamer Bio (immunology/inflammation drugs, IPO in Feb.Partner Kristina Burow keeps a low profile, but entrepreneurs know her as a go-to partner at Arch.īurow has her fingerprints on many of the firm’s big platform companies. To get a feel, read on: Kristina Burow, Arch Venture Partnersīob Nelsen is the quirky, profane, visionary leader of the firm. So who are some of these people who don’t shoot their own investments in the feet? Like Forbes and its Midas List, I don’t have an objective formula for evaluating individual VCs ( Whole firms are opaque, but easier).īut after checking with subscribers of Timmerman Report, I’ve gathered some perspective on who are the ones who quietly go about their business, and do it quite well. When asked to apply the Khosla test to biotech, Bruce Booth of Atlas Venture estimated “20 percent or so are truly value-add.” About four out of every five VCs, he said, actually damage their own investments with bad advice. Vinod Khosla, the tech venture capitalist, has said 95 percent of VCs add zero value to a startup other than cash. Content published on Novem“12 VCs who matter in biotech, but you never read about”, revised and updated October 9, 2019 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |